阴奇男，德国弗莱堡大学医学院博士(M.D.)、华中科技大学同济医学院博士(Ph.D.)，美国临床超声诊断注册医师(RDMS)，美国国立卫生研究院(NIH)临床中心血液诊断实验室研究员，河南科技大学特聘教授, 硕士研究生导师。

美国著名血液免疫学专家Willy A. Flegel教授、诺奖获得者Harvey J. Alter教授团队成员，重点从事肿瘤免疫治疗、精准血型分型、肿瘤标志物检测等研究。参与完成NIH研究项目一项， FDA项目两项， CDC项目一项。多项成果发表在Translational Oncology、Journal of Inflammation Research、Cancer Letters等高水平专业刊物，多次受邀在美国血液协会年会 (AABB)，国际输血协会年会 (ISBT)等作报告。

European Journal of Histochemistry, Functional and Integrative Genomics等刊物编委， British journal of hematology, Journal of Translational Medicine, Cancer Letters等知名刊物审稿人。近5年内，实用新型专利2项，发表SCI论文近30篇，其中第一作者、通讯作者发表近20篇。

[1] 浸润性免疫细胞能量重塑与肿瘤免疫抑制微环境

[2] 红细胞功能与肿瘤进展的机制研究

[3] 肿瘤类器官构建结合多组学分析挖掘肿瘤标志物

研究生课程：系统生物医学

[1] 美国NIH 院内研究项目：血型基因在肿瘤精准检测中的临床应用，2017-至今 （1ZIACL002123）

[2] 美国FDA院内研究项目:可再生生物样本CD59等位基因的标准化特征, 2015-2017 （FY2015‐2017 (MR)）

[3] 美国CDC重点项目：非洲裔美国人血型基因特征及血液疾病检测中的应用，2015-2018 （RASCL727301）

[4] 河南省科技攻关项目：食管鳞癌的能量重塑与肿瘤免疫抑制微环境，2025-至今（252102311044）

[1] H. Ma, L. Shi, J. Zheng, L. Zeng, Y. Chen, S. Zhang, S. Tang, Z. Qu, X. Xiong, X. Zheng and Q. Yin. Advancerd machine learning unveils CD8+ T cell genetic markers enhancing prognosis and immunotherapy efficacy in breast cancer. BMC Cancer, 2024. 24(1): p. 1222.

[2] X. Zheng, S. Zhang, H. Ma, Y. Dong, J. Zheng, L. Zeng, J. Liu, Y. Dai and Q. Yin. Replenishment of TCA cycle intermediates and long-noncoding RNAs regulation in breast cacner. Mol Cell Endocrinol, 2024. 1:592:112321.

[3] Q. Yin, H. Ma, Y. Dong, S. Zhang, J. Wang, J. Liang, L. Mao, L. Zeng, X. Xiong, X. Chen, J. Wang and X. Zheng. The integration of multidisciplinary approaches revealed PTGES3 as a novel drug target for breast cancer treatment. J Transl Med, 2024. 22(1): p. 84

[4] K. Srivastava, Q. Yin, AT. Makuria, M. Rios, A. Gebremedhin and WA. Flegel. CD59 genes: 143 haplotypes of 22.718 nucleotides length by computational phasing in 113 individulas from different ethnicities. Transfusion, 2024. 64(7): p. 1296-1305.  

[5] Q. Yin., Z. Qu., R. Mathew, L. Zeng, Z. Du, Y. Xue, D. Liu, and X. Zheng. Epitranscriptomic orchestrations: Unveiling the regulatory paradigm of m6A, A-to_ editing, and m5C in breast cancer via long noncoding RNAs and microRNAs. Cell Biochem Funct, 2024. 42(3): p. e3996.

[6] Qin, L., D. Gao, Q. Wang, X. Zheng, J. Wang, X. Chen, D. Fu, H. Ma, J. Tan, and Q. Yin. ABO Blood Group and the Risk and Prognosis of Lymphoma. J Inflamm Res, 2023. 16: p. 769-778

[7] Yin, Q., DEL variants: review of molecular mechanisms, clinical consequences and molecular testing strategy. Funct Integr Genomics, 2023. 23(4): p. 318.

[8] Yin, Q., N. Poudel, and Z. Liu. Editorial: Metabolic reprogramming and cancer progression. Transl Oncol, 2023. 28: p. 101610.

[9] Yin, Q. and M. Ouchari. Transfusion management of Africans with RHD variants in China. Transfus Clin Biol, 2023. 30(2): p. 287-293.

[10] X. Zheng, H. Ma, J. Wang, M. Huang, D. Fu, L. Qin and Q. Yin. Energy metabolism pathways in breast cancer progression: The reprogramming, crosstalk, and potential therapeutic targets. Transl Oncol, 2022. 26: p.101534.

[11] X. Zheng, H. Ma, Y. Dong, M. Fang, J. Wang, X. Xiong, J. Liang, M. Han, A. You, Q. Yin and W. Huang. Immune-related biomarkers predict the prognosis and immune response of breast cancer based on bioinformatic analysis and machine learning. Funct Integr Genomics, 2023. 23: p.201.

[12] Q. Yin, H. Ma, G. Bamunuarachchi, X. Zheng and Y. Ma. Long Non-Coding RNAs, Cell Cycle, and Human Breast Cancer. Hum Gene Ther, 2023. 34(11-12): p.481-491.

[13] Y. Zou, B. Liu, L. Li, Q. Yin, J. Tang, Z. Jing, X. Huang, X. Zhu and T. Chi. IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors. Cancer Lett, 2022. 524: p. 121-130.

[14] Yin, Q. and W.A. Flegel. DEL in China: the D antigen among serologic RhD-negative individuals. J Transl Med, 2021. 19(1): p. 439.

[15] Yin, Q., K. Srivastava, D.G. Brust, and W.A. Flegel. Transfusion support during childbirth for a woman with anti-U and the RHD*weak D type 4.0 allele. Immunohematology, 2021. 37(1): p. 1-4.

[16] Liu, C., Y. Xue, M. Ouchari, and Q. Yin, Transfusion management of a Chinese pregnant woman with RHD*DEL1 allele. Transfus Clin Biol, 2021. 28(3): p. 293-295.

[17] Zhou, P., M. Ouchari, Y. Xue, and Q. Yin. In Vitro Generation of Red Blood Cells from Stem Cell and Targeted Therapy. Cell Transplant, 2020. 29: p. 963689720946658.

[18] Yin, Q., Introduction to the Special Issue on Stem Cells and Regenerative Medicine. Eur J Histochem, 2020. 64(s2).

[19] Ghartey-Kwansah, G., Q. Yin, Z. Li, K. Gumpper, Y. Sun, R. Yang, D. Wang, O. Jones, X. Zhou, L. Wang, J. Bryant, J. Ma, J.N. Boampong, and X. Xu, Calcium-dependent Protein Kinases in Malaria Parasite Development and Infection. Cell Transplant, 2020. 29: p. 963689719884888.

[20] Jedidi, I., M. Ouchari, and Q. Yin. Sex chromosomes-linked single-gene disorders involved in human infertility. Eur J Med Genet, 2019. 62(9): p. 103560.

[21] Yin, Q., J. Tang, and X. Zhu. Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer. Brief Funct Genomics, 2019. 18(2): p. 119-128.

[22] Yin, Q., K. Srivastava, J.B. Schneider, A. Gebremedhin, A.T. Makuria, and W.A. Flegel. Molecular analysis of the ICAM4 gene in an autochthonous East African population. Transfusion, 2019. 59(5): p. 1880-1881.

[23] Chen, Z., M. Zhang, Y. Qiao, J. Yang, and Q. Yin. MicroRNA-1297 contributes to the progression of human cervical carcinoma through PTEN. Artif Cells Nanomed Biotechnol, 2018. 46(sup2): p. 1120-1126.

[24] Yin, Q., L. Fischer, C. Noethling, and W.R. Schaefer. In vitro-assessment of putative antiprogestin activities of phytochemicals and synthetic UV absorbers in human endometrial Ishikawa cells. Gynecol Endocrinol, 2015. 31(7): p. 578-81.